用于预测 ADHD 患者对哌醋甲酯治疗反应的神经影像学标志物。
Neuroimaging markers for the prediction of treatment response to Methylphenidate in ADHD.
机构信息
Department of Psychiatry, Trinity College Dublin, Ireland; Department of Psychiatry and Developmental Psychology, University of Nagoya, Japan; Department of Psychiatry, Children's University Hospital, Dublin, Ireland.
出版信息
Eur J Paediatr Neurol. 2013 Nov;17(6):543-51. doi: 10.1016/j.ejpn.2013.04.007. Epub 2013 May 11.
BACKGROUND
Attention Deficit Hyperactivity Disorder (ADHD) is one of the most prevalent mental disorders of childhood, which often continues into adulthood. Methylphenidate is one the most commonly used medication to treat ADHD, however up to 30% of patients do not respond to it.
AIMS
This paper aims to review studies, which employed neuroimaging to predict treatment response to Methylphenidate in ADHD.
METHODS
Systematic literature searches were performed using several databases. Selected articles had to describe an original study that identified neuroimaging markers for the prediction of treatment response to Methylphenidate in ADHD.
RESULTS
Eighty-three articles were found, of which twelve were selected for the present review. Several neuroimaging markers to predict response to MPH were suggested including DAT status, size of medial prefrontal cortex and corpus callosum.
CONCLUSION
Some promising findings have been identified and they should motivate additional work to establish more reliable neuroimaging markers of treatment response to MPH in ADHD.
背景
注意缺陷多动障碍（ADHD）是儿童期最常见的精神障碍之一，通常会持续到成年。哌甲酯是治疗 ADHD 最常用的药物之一，但多达 30%的患者对此没有反应。
目的
本文旨在综述采用神经影像学方法预测 ADHD 患者对哌甲酯治疗反应的研究。
方法
使用多个数据库进行系统文献检索。选择的文章必须描述一项原始研究，该研究确定了神经影像学标志物，以预测 ADHD 患者对哌甲酯治疗的反应。
结果
共发现 83 篇文章，其中 12 篇被选为本次综述。已经提出了一些预测 MPH 反应的神经影像学标志物，包括 DAT 状态、内侧前额叶皮质和胼胝体的大小。
结论
已经确定了一些有希望的发现，这些发现应该促使进一步开展工作，以建立更可靠的 ADHD 患者对 MPH 治疗反应的神经影像学标志物。
Zotero 插件